NCT00297713

Study of an Extended-Release, Crystalline Formulation of Recombinant Human Growth Hormone (ALTU-238) in Growth Hormone Deficient Adults to Determine Pharmacokinetics, Pharmacodynamics, and Drug Safety

A Phase II, Multi-Center, Multi-Dose, Randomized, Open-Label, Parallel Group Study of an Extended-Release, Crystalline Formulation of Recombinant Human Growth Hormone (ALTU-238) in Growth Hormone Deficient Adults to Determine Pharmacokinetics, Pharmacodynamics, and Drug Safety

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 12 (planned)
• Sponsor: Altus Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

ALTU-238 is a long acting crystalline formulation of recombinant human growth hormone (rhGH) that is being developed for the treatment of growth hormone deficiency in adults and children. ALTU-238 is designed to require fewer injections than the currently available formulations of rhGH.

Conditions

• Adult Growth Hormone Deficiency

Interventions

Type	Name	Description
DRUG	ALTU-238

Timeline

• Start date: 2005-07-01
• Completion: 2006-06-01
• First posted: 2006-03-01
• Last updated: 2006-12-13

Locations

3 sites across 1 country: United States